Product Description
Pioglitazone is used with a diet and exercise program and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Pioglitazone is in a class of medications called thiazolidinediones.
Mechanisms of Action: PPAR-g Agonist,STAT5 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: General Diabetes | Type 2 Diabetes | General Diabetes | Type 2 Diabetes | General Diabetes | Type 2 Diabetes
Known Adverse Events: Headache | Pharyngitis | Respiratory Tract Infections | Myalgia | Sinusitis | Diarrhea | Edema | Weight Gain
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Denmark, France, Italy, Korea, Norway, Poland, Spain
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: ANCA Vasculitis|Glomerulonephritis|Type 2 Diabetes
Phase 2: Liposarcoma, Myxoid|Polycystic Ovary Syndrome|Wet Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RENATO | P3 |
Recruiting |
ANCA Vasculitis|Glomerulonephritis |
2027-04-24 |
|
| CT-L03-301 | P3 |
Unknown Status |
Type 2 Diabetes |
2026-05-31 |
|
| SPIOMET4HEALTH | P2 |
Unknown Status |
Polycystic Ovary Syndrome |
2026-02-25 |
|
| 2021-003177-58 | P2 |
Active, not recruiting |
Polycystic Ovary Syndrome |
2025-09-12 |